Prosight Management, LP Buys Shire PLC, Teligent Inc, Cigna Corp, Sells Chimerix Inc, uniQure NV, Centene Corp

• New Purchases: SHPG, TLGT, CI, SRRA, BMRN, ARNA, PIRS, CIVI, KND, AMPE,
• Added Positions: SBRA, RETA, DXCM, AFAM, AKAO, CLVS,
• Reduced Positions: QURE, CNC, CDTX, MGNX, IOVA, EIGR, BLCM, NBRV, QTNT, PRTK,
• Sold Out: CMRX, RXDX, ELGX, RDUS, RARE, LPCN, CFMS, ACHC, ADMS,

For the details of Prosight Management, LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Prosight+Management%2C+LP

1. Shire PLC (SHPG) - 146,114 shares, 14.22% of the total portfolio. New Position
2. Allergan PLC (AGN) - 94,800 shares, 10.39% of the total portfolio. Shares reduced by 3.27%
3. Macrogenics Inc (MGNX) - 445,000 shares, 7.29% of the total portfolio. Shares reduced by 26.77%
4. Sabra Health Care REIT Inc (SBRA) - 580,000 shares, 6.67% of the total portfolio. Shares added by 44.26%
5. Achaogen Inc (AKAO) - 661,054 shares, 5.58% of the total portfolio. Shares added by 15.79%

Prosight Management, LP initiated holding in Shire PLC. The purchase prices were between $125.03 and $159.21, with an estimated average price of $137.68. The stock is now traded at around $168.52. The impact to a portfolio due to this purchase was 14.22%. The holding were 146,114 shares as of 2018-03-31.

Prosight Management, LP initiated holding in Teligent Inc. The purchase prices were between $2.48 and $4.05, with an estimated average price of $3.18. The stock is now traded at around $2.97. The impact to a portfolio due to this purchase was 5.41%. The holding were 2,472,561 shares as of 2018-03-31.

Prosight Management, LP initiated holding in Cigna Corp. The purchase prices were between $164 and $226.22, with an estimated average price of $194.77. The stock is now traded at around $177.54. The impact to a portfolio due to this purchase was 3.52%. The holding were 32,200 shares as of 2018-03-31.

Prosight Management, LP initiated holding in Sierra Oncology Inc. The purchase prices were between $2.03 and $3.75, with an estimated average price of $2.83. The stock is now traded at around $2.37. The impact to a portfolio due to this purchase was 3.42%. The holding were 2,538,525 shares as of 2018-03-31.

Prosight Management, LP initiated holding in Biomarin Pharmaceutical Inc. The purchase prices were between $77.67 and $92.63, with an estimated average price of $85.82. The stock is now traded at around $89.54. The impact to a portfolio due to this purchase was 3.35%. The holding were 63,400 shares as of 2018-03-31.

Prosight Management, LP initiated holding in Arena Pharmaceuticals Inc. The purchase prices were between $30.89 and $44, with an estimated average price of $38.9. The stock is now traded at around $45.62. The impact to a portfolio due to this purchase was 3.1%. The holding were 120,400 shares as of 2018-03-31.

Prosight Management, LP added to a holding in Sabra Health Care REIT Inc by 44.26%. The purchase prices were between $15.96 and $19.09, with an estimated average price of $17.63. The stock is now traded at around $20.04. The impact to a portfolio due to this purchase was 2.05%. The holding were 580,000 shares as of 2018-03-31.

Prosight Management, LP added to a holding in Reata Pharmaceuticals Inc by 72.21%. The purchase prices were between $20 and $30.19, with an estimated average price of $25.84. The stock is now traded at around $31.60. The impact to a portfolio due to this purchase was 1.67%. The holding were 297,750 shares as of 2018-03-31.

Prosight Management, LP added to a holding in DexCom Inc by 108.35%. The purchase prices were between $52.25 and $74.16, with an estimated average price of $59.15. The stock is now traded at around $87.94. The impact to a portfolio due to this purchase was 1.63%. The holding were 65,000 shares as of 2018-03-31.

Prosight Management, LP added to a holding in Almost Family Inc by 49.09%. The purchase prices were between $54.55 and $60.5, with an estimated average price of $57.52. The stock is now traded at around $56.00. The impact to a portfolio due to this purchase was 1.62%. The holding were 135,000 shares as of 2018-03-31.

Prosight Management, LP sold out a holding in Chimerix Inc. The sale prices were between $4.65 and $5.9, with an estimated average price of $5.07.

Prosight Management, LP sold out a holding in Ignyta Inc. The sale prices were between $26.75 and $27, with an estimated average price of $26.93.

Prosight Management, LP sold out a holding in Endologix Inc. The sale prices were between $3.79 and $5.21, with an estimated average price of $4.29.

Prosight Management, LP sold out a holding in Radius Health Inc. The sale prices were between $32.9 and $40.22, with an estimated average price of $36.13.

Prosight Management, LP sold out a holding in Ultragenyx Pharmaceutical Inc. The sale prices were between $44.33 and $58.52, with an estimated average price of $50.21.

Prosight Management, LP sold out a holding in Lipocine Inc. The sale prices were between $1.18 and $3.46, with an estimated average price of $1.67.

Prosight Management, LP reduced to a holding in uniQure NV by 88.02%. The sale prices were between $17.1 and $26.61, with an estimated average price of $21.81. The stock is now traded at around $32.17. The impact to a portfolio due to this sale was -3.65%. Prosight Management, LP still held 34,100 shares as of 2018-03-31.

Prosight Management, LP reduced to a holding in Centene Corp by 67.08%. The sale prices were between $99.38 and $111.59, with an estimated average price of $104.23. The stock is now traded at around $114.73. The impact to a portfolio due to this sale was -3.58%. Prosight Management, LP still held 23,375 shares as of 2018-03-31.

Prosight Management, LP reduced to a holding in Cidara Therapeutics Inc by 28.01%. The sale prices were between $4 and $8.15, with an estimated average price of $6.84. The stock is now traded at around $4.60. The impact to a portfolio due to this sale was -2.34%. Prosight Management, LP still held 1,186,355 shares as of 2018-03-31.

Prosight Management, LP reduced to a holding in Macrogenics Inc by 26.77%. The sale prices were between $18.89 and $32.46, with an estimated average price of $24.29. The stock is now traded at around $21.59. The impact to a portfolio due to this sale was -2.3%. Prosight Management, LP still held 445,000 shares as of 2018-03-31.

Prosight Management, LP reduced to a holding in Iovance Biotherapeutics Inc by 58.6%. The sale prices were between $8.1 and $19.5, with an estimated average price of $15.14. The stock is now traded at around $15.00. The impact to a portfolio due to this sale was -1.77%. Prosight Management, LP still held 209,842 shares as of 2018-03-31.

Prosight Management, LP reduced to a holding in Eiger BioPharmaceuticals Inc by 21.8%. The sale prices were between $8.1 and $16, with an estimated average price of $9.85. The stock is now traded at around $10.75. The impact to a portfolio due to this sale was -1.54%. Prosight Management, LP still held 530,848 shares as of 2018-03-31.